Physician profile
Allison G Cale
NPI 1063753812
$1,560.18
in general payments reported to CMS, 2019-2025
17 companies · $88.21 in 2025
The $88.21 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.29 · 2022: $182 · 2023: $504 · 2024: $716 · 2025: $88.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $476.61 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $251.84 | 2023-2025 | |
| Novo Nordisk INC | $145.02 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $144.64 | 2022-2025 | |
| Abbott Laboratories | $115.55 | 2024 | Freestyle Libre 3 |
| Boston Scientific Corporation | $94.76 | 2023-2024 | Watchman Flx |
| Glaxosmithkline, LLC. | $69.60 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $67.32 | 2023-2024 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $44.16 | 2021-2024 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.84 | 2024 | Jardiance |
| Organon LLC | $29.46 | 2022 | |
| Astellas Pharma US INC | $20.33 | 2024 | Veozah |
| Shield Therapeutics INC | $16.59 | 2023 | Accrufer |
| Merck Sharp & Dohme LLC | $14.79 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.14 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $13.03 | 2021 | |
| Clarus Therapeutics INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Cale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.